SCHEMBL4883873

SCHEMBL4883873

CCN(CC)C1CCN(C(=O)Cn2c(-c3ccc4nc(-c5cccn5C)ccc4c3)c(-c3ccccc3)c3sc(C(=O)O)cc32)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CBX7 O95931 2/20 0.38
CDYL2 Q8N8U2 2/20 0.38
CDYL Q9Y232 2/20 0.38
CDY1; CDY1B Q9Y6F8 1/20 0.34
PIK3CA P42336 2/20 0.33
MTOR P42345 2/20 0.33
POLR1A O95602 1/20 0.32
BRD4 O60885 1/20 0.32
GRM5 P41594 1/20 0.31
MAPT P10636 2/20 0.31
BCHE P06276 1/20 0.31
ACHE P22303 1/20 0.31
GAA P10253 2/20 0.30
ALDH1A1 P00352 2/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
HRH3 Q9Y5N1 1/20 0.30
POLB P06746 1/20 0.30
TSHR P16473 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4883869 0.90 CBX7 (0.35) CBX7CDYL2CDYLCDY1; CDY1BPOLR1A
SCHEMBL4878773 0.89 CBX7 (0.39) CBX7CDYL2CDYLCDY1; CDY1BPIK3CA
SCHEMBL4868402 0.89 CBX7 (0.42) CBX7CDYL2CDYLCDY1; CDY1BPIK3CA
SCHEMBL4874557 0.87 CBX7 (0.38) CBX7CDYL2CDYLCDY1; CDY1BPIK3CA
SCHEMBL4879240 0.87 TDP1 (0.39) CBX7CDYL2CDYLCDY1; CDY1BPIK3CA
SCHEMBL4867721 0.87 CBX7 (0.38) CBX7CDYL2CDYLCDY1; CDY1BPIK3CA
SCHEMBL4875085 0.86 CBX7 (0.37) CBX7CDYL2CDYLCDY1; CDY1BPIK3CA
SCHEMBL4877504 0.85 KCNH2 (0.38) ALDH1A1HRH3POLBTSHRLMNA
SCHEMBL4865010 0.82 TDP1 (0.36) CBX7CDYL2CDYLPIK3CAMTOR
SCHEMBL4877128 0.80 LMNA (0.36) PIK3CAMTORBRD4GRM5GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080051384-A1 ANTIVIRAL AGENTS GENELABS TECHNOLOGIES, INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051384-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 CBX7 2500/4885CDYL2 4283/4885CDYL 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.